GlassScriptPhysician profile
Tai Ho Shin
NPI 1932546082
$9,918.54
in general payments reported to CMS, 2019-2025
50 companies · $3,362 in 2025
The $3,362 reported for 2025 was more than what 84% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $856 · 2020: $418 · 2021: $409 · 2022: $1,537 · 2023: $1,296 · 2024: $2,041 · 2025: $3,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,734 · Travel and Lodging: $877 · Education: $86.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,734.33 |
| Travel and Lodging | $877.41 |
| Education | $86.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,634.72 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,311.71 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Histosonics, INC. | $1,102.41 | 2025 | |
| Novo Nordisk INC | $1,050.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $540.78 | 2021-2025 | Afrezza |
| Amgen INC. | $421.91 | 2022-2025 | Tepezza, Repatha, Evenity |
| Insulet Corporation | $407.77 | 2021-2025 | Omnipod |
| Corcept Therapeutics | $404.04 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $235.65 | 2022-2025 | |
| Abbott Laboratories | $223.33 | 2020-2025 | Freestyle Libre 3, Octrode |
| Amneal Pharmaceuticals LLC | $218.06 | 2022-2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $161.38 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $140.34 | 2021-2025 | Eliquis, Camzyos |
| Medtronic Minimed, INC. | $137.96 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $135.89 | 2022-2025 | Farxiga, Enhertu |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $131.12 | 2024-2025 | Isturisa, Signifor Lar |
| Amarin Pharma, INC. | $124.78 | 2021-2022 | |
| Horizon Therapeutics Plc | $122.96 | 2022 | |
| Novartis Pharmaceuticals Corporation | $120.08 | 2022-2025 | |
| Abbvie INC. | $119.83 | 2022-2025 | Ubrelvy |
| Glaxosmithkline, LLC. | $88.90 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Kyowa Kirin, INC. | $82.84 | 2024-2025 | Crysvita |
| Exact Sciences Corporation | $77.67 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $75.38 | 2021-2025 | Dexcom G6 Transmitter |
| Cequr Corporation | $72.27 | 2023-2025 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $70.25 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Pfizer INC. | $66.51 | 2023-2025 | |
| Beta Bionics, INC. | $60.26 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Merck Sharp & Dohme LLC | $56.80 | 2021-2023 | Verquvo, Steglatro |
| Amphastar Pharmaceuticals, INC. | $56.07 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $54.58 | 2025 | Yorvipath |
| Edwards Lifesciences Corporation | $46.99 | 2024-2025 | Sapien 3 Ultra Resilia |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.43 | 2024-2025 | Caplyta |
| Medtronic, INC. | $31.38 | 2025 | Minimed 780g |
| Averitas Pharma INC. | $25.74 | 2025 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.20 | 2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $23.04 | 2025 | Gemtesa |
| Radius Health, INC. | $21.19 | 2023 | |
| Ibsa Pharma INC. | $20.76 | 2024 | Tirosint, Licart, Flector |
| Alexion Pharmaceuticals, INC. | $20.72 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.77 | 2022 | |
| Boston Scientific Corporation | $18.56 | 2025 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.49 | 2024 | Lifevest |
| Tandem Diabetes Care, INC. | $17.30 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.19 | 2025 | Onpattro |
| Soleno Therapeutics, INC. | $16.10 | 2025 | Vykat Xr |
| Phathom Pharmaceuticals, INC. | $15.99 | 2025 | Voquezna |
| Ge Healthcare | $14.24 | 2024 | |
| Azurity Pharmaceuticals, INC. | $14.14 | 2025 | |
| Janssen Scientific Affairs, LLC | $13.03 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tai Ho Shin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.